Since PD-L1 has a critical role in suppressing anti-tumor immunity, cancer immunotherapy (in particular antibodies that block the PD-1/PD-L1 interaction) was considered to be a revolution in cancer treatment (Postow et al., 2015), and has generated clinical benefit in a subset of patients with EC (Green et al., 2020). This evidence concerns the gene CD274 and cancer.